SCHEMBL1605153

SCHEMBL1605153

CC1SC(N[C@@H](C)c2ccccc2)=NC1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.47
LMNA P02545 1/20 0.47
ROCK1 Q13464 2/20 0.40
AURKB Q96GD4 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
DCLK1 O15075 1/20 0.40
ROCK2 O75116 1/20 0.40
CHEK2 O96017 1/20 0.40
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
IRAK1 P51617 1/20 0.40
PRKX P51817 1/20 0.40
NEK4 P51957 1/20 0.40
PLK1 P53350 1/20 0.40
CSNK1G2 P78368 1/20 0.40
CDC42BPA Q5VT25 1/20 0.40
BRSK1 Q8TDC3 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
STK17A Q9UEE5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1605613 0.85 MAPKAPK2 (0.42) MAPKAPK2IDH1HTT
SCHEMBL1605418 0.84 TAAR1 (0.46) TAAR1LMNAROCK1AURKBCYP3A4
SCHEMBL1605556 0.84 TAAR1 (0.46) TAAR1LMNAROCK1AURKBCYP3A4
SCHEMBL10249360 0.80 HTR6 (0.36) ROCK1ROCK2KDM4ESMN1; SMN2ALDH1A1
SCHEMBL4395222 0.80 HTR6 (0.36) ROCK1ROCK2KDM4ESMN1; SMN2ALDH1A1
SCHEMBL1605884 0.80 MAPKAPK2 (0.45) CYP3A4CYP2C9MAPKAPK2MEN1KMT2A
Hydrochloric Acid SCHEMBL6387633 0.74 HTR7 (0.38) TAAR1LMNAROCK1AURKBCYP3A4
Hydrochloric Acid SCHEMBL6388627 0.74 HTR7 (0.38) TAAR1LMNAROCK1AURKBCYP3A4
SCHEMBL10249354 0.71 IDH1 (0.36) TAAR1LMNAIDH1POLBHDAC1
SCHEMBL10249378 0.71 IDH1 (0.36) TAAR1LMNAIDH1POLBHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541592-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 AMGEN INC. (US) 2013-09-24 US disclosed
US-8541593-B2 Process for making substituted 2-amino-thiazolones AMGEN INC. (US) 2013-09-24 US disclosed
US-8541592-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 AMGEN INC. (US) 2013-09-24 US disclosed
US-8541592-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 AMGEN INC. (US) 2013-09-24 US disclosed
US-8541593-B2 Process for making substituted 2-amino-thiazolones AMGEN INC. (US) 2013-09-24 US disclosed
US-8536345-B2 Process for making substituted 2-amino-thiazolones AMGEN INC. (US) 2013-09-17 US disclosed
US-8536345-B2 Process for making substituted 2-amino-thiazolones AMGEN INC. (US) 2013-09-17 US disclosed
US-20120010256-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB 2012-01-12 US disclosed
US-20120010256-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB 2012-01-12 US disclosed
US-20120010256-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB 2012-01-12 US disclosed
US-20070281938-A1 Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 AMGEN INC. 2007-12-06 US disclosed
US-20070281938-A1 Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 AMGEN INC. 2007-12-06 US disclosed
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2007-08-23 US disclosed
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2007-08-23 US disclosed
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2007-08-23 US disclosed
US-7253196-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 AMGEN, INC. (US) 2007-08-07 US disclosed
US-7253196-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 AMGEN, INC. (US) 2007-08-07 US disclosed
US-7253196-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 AMGEN, INC. (US) 2007-08-07 US disclosed
WO-2007061661-A2 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AMGEN INC. (US) 2007-05-31 WO disclosed
US-20060142357-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 TAAR1 3498/4885LMNA 1744/4885ROCK1 1582/4885
US-20060142357-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD3B1, HSD17B1 TAAR1 3378/4885LMNA 1410/4885ROCK1 531/4885
US-20120010256-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD3B1, HSD17B1 TAAR1 3378/4885LMNA 1410/4885ROCK1 531/4885
US-20070281938-A1 Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 HSD11B1, HSD3B1, HSD17B1 TAAR1 3322/4885LMNA 2340/4885ROCK1 506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.